JP2021521128A5 - - Google Patents

Info

Publication number
JP2021521128A5
JP2021521128A5 JP2020555164A JP2020555164A JP2021521128A5 JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5 JP 2020555164 A JP2020555164 A JP 2020555164A JP 2020555164 A JP2020555164 A JP 2020555164A JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
haloalkyl
heterocyclyl
aryl
Prior art date
Application number
JP2020555164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521128A (ja
JP7361713B2 (ja
JPWO2019204523A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027992 external-priority patent/WO2019204523A1/en
Publication of JP2021521128A publication Critical patent/JP2021521128A/ja
Publication of JP2021521128A5 publication Critical patent/JP2021521128A5/ja
Publication of JPWO2019204523A5 publication Critical patent/JPWO2019204523A5/ja
Application granted granted Critical
Publication of JP7361713B2 publication Critical patent/JP7361713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555164A 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法 Active JP7361713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659068P 2018-04-17 2018-04-17
US62/659,068 2018-04-17
US201862746843P 2018-10-17 2018-10-17
US62/746,843 2018-10-17
PCT/US2019/027992 WO2019204523A1 (en) 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2021521128A JP2021521128A (ja) 2021-08-26
JP2021521128A5 true JP2021521128A5 (https=) 2022-04-11
JPWO2019204523A5 JPWO2019204523A5 (https=) 2022-04-11
JP7361713B2 JP7361713B2 (ja) 2023-10-16

Family

ID=66625250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555164A Active JP7361713B2 (ja) 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法

Country Status (14)

Country Link
US (5) US10968201B2 (https=)
EP (1) EP3781550B1 (https=)
JP (1) JP7361713B2 (https=)
KR (1) KR102815312B1 (https=)
CN (1) CN112313208B (https=)
AU (2) AU2019255717B2 (https=)
BR (1) BR112020021042A2 (https=)
CA (1) CA3096894A1 (https=)
DK (1) DK3781550T3 (https=)
ES (1) ES3010282T3 (https=)
IL (1) IL277963B2 (https=)
MX (1) MX2020010879A (https=)
SG (1) SG11202010153WA (https=)
WO (1) WO2019204523A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018255300B2 (en) * 2017-04-18 2021-10-28 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN115448882A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN115448913A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的双环化合物
CN114085167A (zh) * 2021-12-13 2022-02-25 华中药业股份有限公司 一种杂质ts-3a的制备方法
WO2024102968A1 (en) * 2022-11-10 2024-05-16 Tempest Therapeutics, Inc. Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
CN118164967A (zh) * 2022-12-08 2024-06-11 武汉人福创新药物研发中心有限公司 一种ep2、ep4受体拮抗剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2035376B1 (en) * 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
JP5408434B2 (ja) * 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010121382A1 (en) * 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
RU2560818C2 (ru) 2009-04-21 2015-08-20 Эппл Инк Способ и устройство для определения индикатора качества канала в сетях связи, работающих в режиме mu-mimo
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9655887B2 (en) 2013-05-23 2017-05-23 Bayer Pharma Aktiengesellschaft Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
CN108430992A (zh) * 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
TWI730032B (zh) * 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
HUE057799T2 (hu) 2016-07-07 2022-06-28 Ono Pharmaceutical Co EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció
AU2018255300B2 (en) * 2017-04-18 2021-10-28 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN115448882A (zh) 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN119487006A (zh) 2022-02-24 2025-02-18 广东新契生物医药科技有限公司 作为pge2受体拮抗剂的酰胺化合物

Similar Documents

Publication Publication Date Title
JP2021521128A5 (https=)
DK2958907T3 (en) Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019535744A5 (https=)
JP2021523221A5 (https=)
RU2011107278A (ru) Пиримидиновые соединения, композиции и способы применения
JP2013056886A5 (https=)
JP2019094345A5 (https=)
RU2014122335A (ru) ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
JP2018504437A5 (https=)
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2015531764A5 (https=)
JP2022071077A5 (https=)
JP2014521609A5 (https=)
JP2020507625A5 (https=)
JP2020507624A5 (https=)
JP2010506919A5 (https=)
JP2007517007A5 (https=)
JP2009503110A5 (https=)
JP2018532786A5 (https=)
JPWO2019204523A5 (https=)
JP2021532158A5 (https=)
JPWO2021007307A5 (https=)
JP2020518621A5 (https=)